Skip to main content
ALKS
NASDAQ Life Sciences

Alkermes CEO Richard Pops to Retire; COO Blair Jackson Appointed Successor

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
8
Price
$32.405
Mkt Cap
$5.351B
52W Low
$25.165
52W High
$36.316
Market data snapshot near publication time

summarizeSummary

After 35 years, Richard Pops will retire as CEO of Alkermes plc, effective July 31, 2026, with current COO Blair Jackson stepping into the role on August 1, 2026. Pops will remain non-executive Chairman.


check_boxKey Events

  • CEO Retirement Announced

    Richard F. Pops will retire from his position as Chief Executive Officer of Alkermes plc, effective July 31, 2026, following 35 years of service in the role.

  • New CEO Appointed

    Blair C. Jackson, currently the company's Executive Vice President and Chief Operating Officer, has been appointed to serve as Chief Executive Officer, effective August 1, 2026.

  • Pops to Remain Chairman and Advisor

    Mr. Pops will continue to serve as non-executive Chairman of the Board and as a Senior Advisor to the company through December 31, 2026, facilitating a smooth transition.

  • Transition Compensation Details

    Mr. Pops' continued service includes a monthly cash retainer of $75,000, a pro-rated 2026 annual cash bonus, a time-based restricted stock unit award, and an annual retainer for his non-executive Chairman role.


auto_awesomeAnalysis

This 8-K announces a significant leadership transition for Alkermes plc, with long-serving CEO Richard Pops retiring after 35 years. The appointment of current COO Blair Jackson as his successor, coupled with Mr. Pops remaining as non-executive Chairman and Senior Advisor, signals a planned and orderly transition. This internal promotion suggests continuity in strategy, which may reassure investors following the company's recent acquisition of Avadel Pharmaceuticals and its latest earnings report. The structured handover aims to maintain stability and leverage existing leadership expertise during this period of change.

At the time of this filing, ALKS was trading at $32.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.4B. The 52-week trading range was $25.17 to $36.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ALKS - Latest Insights

ALKS
Apr 06, 2026, 5:04 PM EDT
Filing Type: DEF 14A
Importance Score:
8
ALKS
Mar 27, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
7
ALKS
Feb 25, 2026, 9:31 AM EST
Filing Type: 10-K
Importance Score:
8
ALKS
Feb 25, 2026, 9:31 AM EST
Filing Type: 8-K
Importance Score:
8
ALKS
Feb 25, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
8
ALKS
Feb 12, 2026, 7:37 AM EST
Filing Type: 8-K
Importance Score:
9
ALKS
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
ALKS
Jan 06, 2026, 7:07 AM EST
Filing Type: 8-K
Importance Score:
9